<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99761">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805895</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000718</org_study_id>
    <nct_id>NCT01805895</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients</brief_title>
  <acronym>MACH</acronym>
  <official_title>Minocycline in Acute Cerebral Hemorrhage (MACH) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MACH Trial is a pilot study of 400mg minocycline over five days in acute intracerebral
      hemorrhage patients. The study will evaluation the safety and efficacy of minocycline in
      intracerebral hemorrhage patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MACH is a randomized trial of minocycline in intracerebral hemorrhage. 24 total subjects
      will be randomly assigned to minocycline or control (1:1). The first dose will be given
      intravenously. Subsequent doses will be given orally every 24 hours for a total of five
      doses. The study will test to see if the medication is safe in intracerebral hemorrhage. The
      pharmacokinetics of minocycline in intracerebral hemorrhage will be determined and the
      impact of minocycline on blood biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>modified Rankin Scale</measure>
    <time_frame>90 days</time_frame>
    <description>A blinded assessor will perform the modified Rankin Scale after 90 days to determine functional outcome. This will serve as our efficacy endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse events will be asses for 90 days. This will serve as our safety endpoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will not receive any minocycline. This arm will receive standard of care treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Dynacin, Minocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Intracerebral hemorrhage documented by CT scan

          -  The first dose of the drug can be administered within 12 hours of time last known to
             be at baseline

        Exclusion Criteria:

          -  Allergy to tetracycline antibiotics

          -  Pregnancy or suspected pregnancy (pregnancy test will be done on women of
             child-bearing potential)

          -  Hepatic and/or renal insufficiency (LFT's &gt;3x upper limit of normal; Creatinine
             &gt;2mg/dL)

          -  History of intolerance to minocycline

          -  National Institutes of Health Stroke Scale score of 4 or less

          -  Glasgow Coma Scale score of 5 or less

          -  Surgical evacuation of hematoma planned within 24 hours

          -  Secondary intracerebral hemorrhage resulting from trauma, arteriovenous malformation,
             aneurysm, tumor or other causes

          -  Thrombocytopenia (platelet count &lt;75,000/mm3) or coagulopathy (INR &gt;1.4)

          -  Previously not independent (prestroke modified Rankin scale score &gt;2)

          -  Suspected of not being able to comply with the study protocol

          -  Unlikely to be available for 90 day follow-up

          -  Pre-existing Do Not Resuscitate (DNR) order or indication that a new DNR order will
             be implemented within the first 48 hours of hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Switzer, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey A Switzer, DO</last_name>
    <phone>706-721-1691</phone>
    <email>jswitzer@gru.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Anne Park, RN</last_name>
    <phone>706-721-0193</phone>
    <email>mpark@gru.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgia Health Sciences University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Switzer, DO</last_name>
      <phone>706-721-1691</phone>
      <email>jswitzer@gru.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Switzer, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Hess, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Askiel Bruno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fenwick Nichols, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hartmut Gross, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Fagan, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 9, 2016</lastchanged_date>
  <firstreceived_date>March 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgia Regents University</investigator_affiliation>
    <investigator_full_name>Jeffrey Switzer</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Acute Intracerebral Hemorrhage</keyword>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Hemorrhagic stroke</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Minocycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
